EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality

Danilo Menichelli, Vito Maria Daniele Cormaci, Gianluca Gazzaniga, Irma Bisceglia, Massimiliano Camilli, Daniela Poli, Emilia Antonucci, Roberto Pola, Paolo Santini iD, Pasquale Pignatelli, Daniele Pastori iD, START2 Registry Investigators

Cancer · 2026

DOI: 10.1002/cncr.70501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Danilo Menichelli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Surgical Specialty and Anesthesiology Paride Stefanini, PhD School in Advances in Cardio-Thoracic and Vascular Pathoph…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Neoplasms, Warfarin. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atrial fibrillation (AF) patients with cancer are frequently treated with vitamin K antagonists (VKAs). Direct oral anticoagulants (DOACs) benefit according to VKA quality has not been investigated in this high‐risk population. The authors compared DOACs with VKAs on mortality, cardiovascular events (CVEs), and bleeding risk across time‐in‐therapeutic‐range (TiTR) strata (< or ≥70%).

Methods

AF patients with cancer from the nationwide Italian Survey on Anticoagulated Patients Register on oral anticoagulants were included. Propensity score matching (PSM) was performed. Results were expressed as hazard ratio (HR) and 95% confidence interval (CI) for all‐cause mortality and as subdistribution HR (sHR) for CVEs and bleeding risk. Numbers‐needed‐to‐treat (NNT) and numbers‐needed‐to‐harm (NNH) were calculated. VKA patients were stratified by TiTR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsNeoplasmsWarfarinHumansFemaleAgedMaleAdministration, OralHemorrhageAged, 80 and overStrokeVitamin KItaly

Stichwörter der Autor:innen

atrial fibrillationcancercardiovascular eventsdirect oral anticoagulantsmortality

Substanzen

AnticoagulantsWarfarinVitamin K

Autor:innen und Institutionen

  • Department of General Surgery, Surgical Specialty and Anesthesiology Paride Stefanini, PhD School in Advances in Cardio-Thoracic and Vascular Pathophysiology and Imaging, Sapienza University of Rome, Rome, Italy.
  • Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Integrated Cardiology Services, Department of Cardio-Thoracic-Vascular, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
  • Department of Cardiovascular Sciences CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

ORCID-Profile: Paolo Santini, Daniele Pastori

Zitieren

APA

Menichelli, D., Cormaci, V. M. D., Gazzaniga, G., Bisceglia, I., Camilli, M., Poli, D., Antonucci, E., Pola, R., Santini, P., Pignatelli, P., Pastori, D., & START2 Registry Investigators (2026). Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality. Cancer. https://doi.org/10.1002/cncr.70501

Vancouver

Menichelli D, Cormaci VMD, Gazzaniga G, Bisceglia I, Camilli M, Poli D, et al. Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality. Cancer. 2026. doi:10.1002/cncr.70501

BibTeX
@article{Menichelli2026,
  author = {Menichelli, Danilo and Cormaci, Vito Maria Daniele and Gazzaniga, Gianluca and Bisceglia, Irma and Camilli, Massimiliano and Poli, Daniela and Antonucci, Emilia and Pola, Roberto and Santini, Paolo and Pignatelli, Pasquale and Pastori, Daniele and START2 Registry Investigators, START2 Registry Investigators},
  title = {Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70501}
}
Kostenlos starten →